|
Preclinical Trials Approved by the VA Boston Healthcare System
December 7, 2011
The VA Boston Healthcare System has approved preclinical trials with LambdaVision scientists, which will be undertaken in collaboration with Dr. Ralph Jensen and the Center for Innovative Visual Rehabilitation.
LVI Hires Chief Operating Officer, Maximilian Vargas
November 15, 2011
LambdaVision is happy to announce that Maximilian Vargas will serve as COO for the company. Max is currently completing his Ph. D. dissertation at the University of Connecticut Health Center, and served as a consultant for LVI to help develop an overall marketing and commercialization strategy. Meet Max here!
LVI CEO Nicole Wagner Presents at State of Connecticut Economic Summit
October 6, 2011
Connecticut Governor Dannel P. Malloy held a Economic Summit at the Connecticut Convention Center, launching his Startup Connecticut initiative. Details of the Summit can be found in this article, published in the Hartford Courant. Startup Connecticut is an effort spearheaded by the Department of Community and Economic Development (DECD) that seeks to assist entrepreneurship and job creation, with an emphasis on small business and innovative ideas. LambdaVision CEO Nicole Wagner represented the startup companies of Connecticut and presented her research on protein-based artificial retinas.
Hartford Business Journal Discusses Recent LVI Startup Funds
October 4, 2011
The Hartford Business Journal (HBJ) recently published an article discussing LambdaVision, Inc. and the Pre-Seed Funding awarded by Connecticut Innovations. The article can be found here.
LVI Receives Pre-Seed Funding From Connecticut Innovations
October 3, 2011
Connecticut Inovations (CI) has awarded LambdaVision, Inc. $40,000.00 through its Pre-Seed Fund. An article discussing the financial committment and the research involved at LVI can be read here.
LVI Signs Contract with VA Boston Healthcare System
September 15, 2011
LambdaVision has signed a contract with the VA Boston Healthcare System, which includes a series of preclinical trials for the protein-based artificial retina. In collaboration with Dr. Ralph Jensen, researchers from LVI will perform several experiments in order to investigate the neural response generated by the retinal implants on excised rabbit retinas. These ex vivo studies are an important step forward in testing the efficacy and performance of the bacteriorhodopsin thin films, and will serve as a platform for future clinical trials.
Protein Society 2011, Boston, MA
July 25, 2011
LambdaVision, Inc. CEO Nicole Wagner was awarded The Protein Science Young Investigator Travel Grant to present her research on protein-based artificial retinas.
|
